Clinical Trials

8 enrolled

Colorectal Neoplasms

NCT04844385 2024-02-09

Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

124 enrolled

Esophageal Squamous Cell Carcinoma

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

DermatologicLymphoidThoracic

499 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT06221774 2024-01-24

Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors

42 enrolled

Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT05576961 2024-01-23

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Phase EARLY_PHASE1 Unknown

Solid Tumor

NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

40 enrolled

EGFR Positive Non-small Cell Lung Cancer

NCT04025931 2023-12-29

Chidamide Combined With Toripalimab in Sarcoma

74 enrolled

Sarcoma

NCT05580445 2023-11-22

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

114 enrolled

Advanced Pancreatic Cancer

NCT06081582 2023-10-13

Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC

33 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06078982 2023-10-12

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

6 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT05994456 2023-08-16

Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer

24 enrolled

Stomach Neoplasms

NCT04135690 2023-08-15

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Carcinoma, Hepatocellular

NCT04653480 2023-07-17

Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC

61 enrolled

Colorectal Neoplasms

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05451407 2023-07-07

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

50 enrolled

Melanoma

NCT03810339 2023-06-27

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

35 enrolled

Solid Tumor

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

43 enrolled

Melanoma

NCT05478473 2023-06-18

Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma

Phase NA Unknown

43 enrolled

Melanoma

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

30 enrolled

Non Small Cell Lung Cancer Recurrent

NCT05723432 2023-04-27

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

84 enrolled

Melanoma

NCT05817201 2023-04-18

Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Phase 2/3 Unknown

Esophageal Neoplasms

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

45 enrolled

Nasopharyngeal Carcinoma

NCT04172805 2023-04-12

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

70 enrolled

Sarcoma

NCT05803915 2023-04-07

Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04667793 2023-04-04

Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor

15 enrolled

Thymic epithelial tumor

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Biliary Tract Neoplasms, Liver Neoplasms

NCT04211168 2023-03-29

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

44 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT04368078 2023-03-29

Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma

76 enrolled

Carcinoma, Hepatocellular

NCT05763927 2023-03-10

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

44 enrolled

Rectal Neoplasms

NCT05163483 2023-03-06

Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer

87 enrolled

Esophageal Squamous Cell Carcinoma

NCT05749575 2023-03-01

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

28 enrolled

Breast

Breast Neoplasms

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

21 enrolled

Nasopharyngeal Carcinoma

NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

88 enrolled

Head and Neck Squamous Cell Cancer

NCT05652712 2022-12-15

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Unknown

200 enrolled

Lung Neoplasms

NCT05350943 2022-10-18

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

70 enrolled

Biliary Tract Adenocarcinoma

NCT03864211 2022-09-29

Thermal Ablation Followed by Immunotherapy for HCC

145 enrolled

Carcinoma, Hepatocellular

NCT05493332 2022-08-18

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC

93 enrolled

Carcinoma, Hepatocellular

NCT05502393 2022-08-16

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

118 enrolled

Advanced Solid Tumors

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05466019 2022-07-20

A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)

30 enrolled

PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05448183 2022-07-07

An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

45 enrolled

Cholangiocarcinoma

NCT04398056 2022-07-06

Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma

22 enrolled

Nasopharyngeal Carcinoma

NCT05420597 2022-06-15

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

61 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT05369286 2022-05-11

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

28 enrolled

Solid Tumor

NCT05162196 2022-05-02

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

57 enrolled

Small Cell Lung Carcinoma

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

41 enrolled

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

32 enrolled

Nasopharyngeal Carcinoma

NCT05342506 2022-04-22

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies